Recent Quotes

My Watchlist

Indicators

Merus N.V. CS (NQ: MRUS )

52.16 -0.80 (-1.51%)

Streaming Delayed Price Updated: 1:05 PM EST, Nov 12, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	103,312
Open	52.34
Bid (Size)	52.03 (8)
Ask (Size)	52.29 (8)
Prev. Close	52.96
Today's Range	51.12 - 52.83
52wk Range	22.01 - 61.61
Shares Outstanding	46,530,884
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Merus to Present at Upcoming Investor Conferences

November 06, 2024

From Merus N.V.

Via GlobeNewswire

Merus Receives FDA extension of PDUFA for zenocutuzumab

November 05, 2024

From Merus N.V.

Via GlobeNewswire

Performance

YTD	+82.25%	+82.25%
1 Month	-0.02%	-0.02%
3 Month	+0.79%	+0.79%
6 Month	+13.76%	+13.76%
1 Year	+132.03%	+132.03%

More News

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

October 31, 2024

From Merus N.V.

Via GlobeNewswire

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

September 30, 2024

From Merus N.V.

Via GlobeNewswire

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

September 17, 2024

From Merus N.V.

Via GlobeNewswire

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 06, 2024

From Merus N.V.

Via GlobeNewswire

MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024

August 01, 2024

Via InvestorPlace

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

August 01, 2024

From Merus N.V.

Via GlobeNewswire

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

July 24, 2024

From Merus N.V.

Via GlobeNewswire

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

July 08, 2024

From Merus N.V.

Via GlobeNewswire

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

July 01, 2024

From Merus N.V.

Via GlobeNewswire

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

June 03, 2024

From Merus N.V.

Via GlobeNewswire

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

June 02, 2024

From Merus N.V.

Via GlobeNewswire

Merus Announces Pricing of Upsized Public Offering of Common Shares

May 29, 2024

From Merus N.V.

Via GlobeNewswire

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 29, 2024

From Merus N.V.

Via GlobeNewswire

Merus N.V. Announces Proposed Public Offering of Common Shares

May 28, 2024

From Merus N.V.

Via GlobeNewswire

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

May 28, 2024

Via Benzinga

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

May 28, 2024

From Merus N.V.

Via GlobeNewswire

Crude Oil Rises 1%; Verastem Shares Slide

May 24, 2024

Via Benzinga

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session

May 24, 2024

Via Benzinga

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

May 24, 2024

Via Benzinga

Nasdaq Gains 1%; Intuit Shares Plunge

May 24, 2024

Via Benzinga

Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High

May 24, 2024

Via Investor's Business Daily

Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday

May 24, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

May 24, 2024

Via InvestorPlace

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.